MarketCap
Facebook
X
TelegramQuarterly report 2022-Q2
added 05-23-2026
La Jolla Pharmaceutical Company Total Liabilities 2011-2026 | LJPC
Annual Total Liabilities La Jolla Pharmaceutical Company
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 168 M | 160 M | 188 M | 168 M | 31.3 M | 9.76 M | 4.82 M | 2.08 M | 1.09 M | 216 K | 20.7 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 188 M | 216 K | 68.6 M |
Quarterly Total Liabilities La Jolla Pharmaceutical Company
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 169 M | 167 M | 168 M | 169 M | 167 M | 162 M | 160 M | 166 M | 183 M | 180 M | 188 M | 184 M | 182 M | 177 M | 168 M | 162 M | 157 M | 29.5 M | 31.3 M | 31.3 M | 31.3 M | 31.3 M | 9.76 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 188 M | 9.76 M | 134 M |
Total Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
6.06 M | - | 5743.5 % | $ 69.7 M |  Canada |
 |
MorphoSys AG
MOR
|
1.98 B | - | 2.43 % | $ 254 M |  Germany |
 |
Happiness Biotech Group Limited
HAPP
|
6.56 M | - | 1.35 % | $ 17.8 M |  China |
 |
Coherus BioSciences
CHRS
|
197 M | $ 1.64 | 1.86 % | $ 192 M |  USA |
 |
AgeX Therapeutics
AGE
|
6.99 M | - | -10.17 % | $ 12.2 K | USA |
 |
I-Mab
IMAB
|
707 M | - | - | $ 866 M | China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
6.45 B | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
20.4 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
215 M | - | 2.54 % | $ 160 B | France |
 |
BioNTech SE
BNTX
|
2.76 B | $ 92.25 | 0.12 % | $ 22.3 B | Germany |
 |
AstraZeneca PLC
AZN
|
65.4 B | - | - | $ 96.9 B |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.16 M | - | -1.52 % | $ 24.7 M | USA |
 |
Athira Pharma
ATHA
|
64.4 M | - | - | $ 269 M | USA |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
71.5 M | - | 0.74 % | $ 768 M |  Israel |
 |
Compugen Ltd.
CGEN
|
18.5 M | $ 2.65 | -5.36 % | $ 248 M | Israel |
 |
Abcam plc
ABCM
|
330 M | - | - | $ 4.9 B | Britain |
 |
Galera Therapeutics
GRTX
|
645 K | - | -32.59 % | $ 7.61 M | USA |
 |
Midatech Pharma plc
MTP
|
6.77 M | - | -18.52 % | $ 27.3 M | Britain |
|
Enlivex Therapeutics Ltd.
ENLV
|
392 M | $ 0.68 | -4.67 % | $ 31.1 M | Israel |
 |
Esperion Therapeutics
ESPR
|
768 M | $ 3.12 | -0.32 % | $ 649 M | USA |
 |
Eton Pharmaceuticals
ETON
|
66 M | $ 31.29 | -3.99 % | $ 842 M | USA |
 |
Affimed N.V.
AFMD
|
104 M | - | -34.95 % | $ 21.5 M | Germany |
|
Forte Biosciences
FBRX
|
21.8 M | $ 21.94 | 1.62 % | $ 284 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
1.1 B | - | - | - |  Russia |
 |
Checkmate Pharmaceuticals
CMPI
|
9.38 M | - | - | $ 231 M | USA |
 |
Celyad Oncology SA
CYAD
|
35.1 M | - | - | $ 12.5 M |  Belgium |
 |
Berkeley Lights
BLI
|
84 M | - | -7.31 % | $ 87 M | USA |
 |
Generation Bio Co.
GBIO
|
145 M | - | - | $ 344 M | USA |
 |
IMV
IMV
|
38 M | - | - | $ 13.1 M | Canada |
 |
Akero Therapeutics
AKRO
|
75.8 M | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
45.1 M | - | 0.23 % | $ 488 M | USA |
 |
Grifols, S.A.
GRFS
|
12.8 B | $ 8.01 | - | $ 5.44 B |  Spain |
 |
Ayala Pharmaceuticals
AYLA
|
7.43 M | - | - | $ 7.46 M | Israel |
 |
Heron Therapeutics
HRTX
|
242 M | $ 0.88 | 2.85 % | $ 147 M | USA |
 |
Cyclacel Pharmaceuticals
CYCCP
|
1.34 M | - | -4.36 % | $ 27 M | USA |
 |
Freeline Therapeutics Holdings plc
FRLN
|
34.2 M | - | - | $ 384 M | Britain |
 |
Gracell Biotechnologies
GRCL
|
281 M | - | - | $ 3.37 B | China |
 |
Anika Therapeutics
ANIK
|
42.3 M | $ 14.89 | 0.07 % | $ 214 M | USA |
 |
Advaxis
ADXS
|
2.3 M | - | -9.65 % | $ 45.9 M | USA |
 |
InflaRx N.V.
IFRX
|
13.7 M | $ 2.74 | 4.98 % | $ 184 M | Germany |
 |
Aeterna Zentaris
AEZS
|
17.6 M | - | 5.93 % | $ 314 M | Canada |
 |
Aeglea BioTherapeutics
AGLE
|
62.5 M | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
470 M | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
37.2 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
43.5 M | - | 1.93 % | $ 17.4 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
3.45 M | $ 3.44 | 1.18 % | $ 5.66 M | Israel |
 |
Aptose Biosciences
APTO
|
37.2 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
28.4 M | - | -39.0 % | $ 4.57 M | USA |
 |
Albireo Pharma
ALBO
|
126 M | - | -0.23 % | $ 916 M | USA |
 |
AlloVir
ALVR
|
42.9 M | - | 4.14 % | $ 49.1 M | USA |